BCLS II Equity Opportunities LP 13D and 13G filings for Aeglea BioTherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 06:04 am Purchase |
2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
BCLS II Equity Opportunities LP | 213,908 8.700% |
100,000 (+87.79%) |
Filing |
| 2022-02-14 06:40 am Purchase |
2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
BCLS II Equity Opportunities LP | 113,908 5.800% |
5,908 (+5.47%) |
Filing |
| 2020-06-09 11:45 am Purchase |
2020-04-30 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
BCLS II Equity Opportunities LP | 108,000 6.100% |
108,000 (New Position) |
Filing |